SEATTLE, May 20, 2013 /PRNewswire/ — Pacific Biomarkers and Clinigene International are set to unveil their collaborative laboratory solutions for developers of biosimilars at the 2013 AAPS/National Biotechnology Conference May 20-22 at the Sheraton San Diego Hotel and Marina, San Diego, CA. Attendees will have the opportunity to speak with company representatives at their collaborative seminar, “Biosimilarity, Immunogenicity and Biomarker Development: Paths That Cross” on May 21 from 1-2 p.m. in the conference’s Spinnaker Room.
The Seattle based company Pacific Biomarkers first partnered with Bangalore based Clinigene International in December 2011 to develop laboratory solutions, encompassing immunogenicity and biomarkers. This joint venture brings together the experience and authority of Pacific Biomarkers and the advantage of Clinigene’’s extensive laboratory services located in India for clients engaged in the development of biosimilars.
According to IMS Health, Inc., by 2015 biosimilars sales for the U.S. are estimated at $1.9 to 2.6 billion up from $378 million for the year to first half of 2011. The strategic partnership of Pacific Biomarkers and Clinigene International paves the way for advancements in this emerging market of biomarker assay development and testing throughout the United States and abroad.
“At Pacific Biomarkers we have provided expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity and nutrition to many of the world’’s largest pharmaceutical, biotech and diagnostic companies,” said Ron Helm , Chairman and Chief Executive Officer of Pacific Biomarkers. “Our collaboration with Clinigene now offers our clients careful attention from early development through regulatory approval. Additionally, companies will see shortened timelines, decreased costs and a continuity of research and fluid knowledge transfer. There is no longer the need to contract with multiple CROs, thereby safeguarding the value of our clients’ assays, therapies and devices.”
Both laboratories are CAP/CLIA and GLP certified and produce strong analytical data that meets regulatory compliance and quality assurance for clinical biomarkers, immunogenicity assay development, technology transfers and validations, PK/PD markers, cell-based assays, and LC/MS/MS support.
Register for the 2013 AAPS/National Biotechnology Conference “Biosimilarity, Immunogenicity and Biomarker Development: Paths That Cross” seminar at Booth #108 at the conference.
SOURCE Pacific Biomarkers